Pfizer taps BC for real-world cardiovascular research drive

Pfizer HQ
Pfizer's headquarters are in New York City. (Norbert Nagel/CC BY-SA 3.0)

Pfizer has teamed up with BC Platforms to generate real-world evidence on cardiovascular diseases. The collaboration will leverage BC’s technology and Finnish health records to better understand atrial fibrillation patients.

Multiple organizations are involved in the initiative. The patient data will come from Turku University Hospital and other healthcare providers. BC is providing technology and research platforms, including access to data bank network BCRQUEST. And BC-partner Microsoft is handling the cloud infrastructure needed to index the information and make it available globally.

Pfizer is the beneficiary of these organizations’ efforts to make data accessible and analyzable. The Big Pharma is looking to the project to yield insights into complex cardiovascular diseases.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We need data to fully understand and provide the best treatment outcomes for patients,” Jaakko Parkkinen, country medical director at Pfizer, said in a statement. “We believe that combining our expertise in treatment of cardiovascular diseases with BC Platforms' advanced genomic and clinical data management solutions through BCRQUEST.COM, we can gather and analyse important real world evidence to generate optimal patient outcomes.”

Landing Pfizer as a client caps off a big 12 months for BC. Since closing a $10 million series B in May, BC has rolled out its BCRQUEST platform and quickly landed three big-name clients: Amgen, Biogen and Pfizer. The drug developers are using the platform to generate real-world evidence in therapeutic areas of interest, including cardiovascular disease, oncology and multiple sclerosis.

BCRQUEST’s ability to generate such evidence is underpinned by access to genomic and clinical data held by biobanks around the world. BC has aggregated the resources—freeing drug developers from tackling potentially-tricky data harmonization tasks—and added an analytical layer to help companies make sense of the resource.   

Suggested Articles

Belgian devicemaker Miracor Medical received a breakthrough designation from the FDA for its treatment designed to limit the damage of a heart attack.

Following an FBI raid and the replacement of its leadership, it’s come to light that the data behind uBiome’s microbiome test may contain flaws.

The National Institutes of Health has tapped the genomics firm Color to help participants understand and act on their results.